



**thsti**

ट्रांसलेशनल स्वास्थ्य विज्ञान  
एवं प्रौद्योगिकी संस्थान

TRANSLATIONAL HEALTH SCIENCE  
AND TECHNOLOGY INSTITUTE

(An autonomous Institute of the Dept. of Biotechnology, Ministry of Science & Technology, Govt. of India)

NCR-Biotech Science cluster, 3<sup>rd</sup> mile stone, Faridabad-Gurgaon Expressway, Faridabad

Phone No. : 0129-2876300 Fax No: 0129-2876 402 Website: [www.thsti.res.in](http://www.thsti.res.in)

**Expression of Interest (EOI) is invited from**

**Pvt or Ltd Companies for Evaluation of Small Molecule Test Compound to determine its effect against HIV infection, using a mice model that accurately produces a full human immune system infected by HIV**

**(EOI No.: THSTI/EOI/DDRC/19-20)**

**16 Jul, 2019**



## NOTICE INVITING EOI

**Ref. No. THSTI/EOI/DDRC/19-20**

**Date: 16 Jul, 2019**

On behalf Executive Director, THSTI sealed Expression of Interest (EOI) is invited from eligible and interested firms for “Evaluation of Small Molecule Test Compound to evaluate its effect against HIV, using a mice model that accurately produces a full human immune system infected by HIV infection” under CRS BIRAC funded project with reference number BT/CRS0200/CRS -10/16 titled *Development and PoC validation of a novel approach to treat HIV infection by integrating anti-viral activity with stimulation of host cell innate immunity*”.

The complete set of Expression of Interest document may be downloaded from our website: [www.thsti.res.in](http://www.thsti.res.in) and CPP Portal [www.eprocure.gov.in](http://www.eprocure.gov.in).or may also be collected from the Purchase Section, THSTI, Faridabad from 17 Jul 2019 to 16 Aug 2019 between 10:00 AM to 15:00 PM at free of cost.

All future corrigendum/amendments etc., if any, will be notified only on the THSTI website and no separate advertisement will be released for the same. Prospective bidders are therefore advised to regularly visit the THSTI website for any such updates.

It may be noted that this is invitation for EOI and should not be construed as the Tender/Request for Proposal (RFP) in any form and would not be binding on the institute in any manner whatsoever.

**Section Officer (S&P)  
THSTI**

**DATA SHEET / TIME LINES**

Document No	THSTI/EOI/DDRC/19-20
Name of the Work	Evaluation of small molecule test compound to determine its effect against HIV infection, using a mice model that accurately produces a full human immune system infected by HIV
Brief Scope of Work	<p>This Eoi is intended to evaluate a small molecule drug lead for its efficacy evaluation against HIV infection in Humanized mice experiment infected with HIV. There is a plan to have minimum 7 groups of humMice with minimum 6 mice in each group i.e. Group G1: Vehicle Control; G2: Positive/Standard control (Elvitegravir); G3: Dose-X; G4: Dose-3X; G5: Dose-10X; G6: Standard HAART; G7: HAART with Dose 2</p> <p>The drug lead shall be dosed single dose/day using oral gavage for 4 weeks using appropriate formulation and different predetermined efficacy points shall be studied.</p>
Estimated Cost of the Project	INR 1.12 Crore
Estimated Period of Contract	120 days
Start date of sale of Eoi Document	17/07/19
Pre-Eoi meeting	24/07/19 at 15:00 PM
Revision of EOI ( If Required )	26/07/19
Last date & time of submission of EOI applications hard copy	19/08/19 by 15:00 PM
Date & Time of Opening of EOI applications	19/08/19 by 16:00 PM

## Expression of Interest (EOI)

### **Introduction:**

Translational Health Science and Technology Institute (THSTI) is an autonomous Institute of the Department of Biotechnology, Ministry of Science and Technology, Govt. of India. The institute is an integral part of the interdisciplinary NCR Biotech Science Cluster located at Faridabad, and is designed as a dynamic, interactive organization with the mission to conduct innovative translational research and to develop research collaborations across disciplines and professions to translate concepts into tangible products to improve human health.

This work under consideration pertains to an ongoing project funded by CRS BIRAC scheme with reference number BT/CRS0200/CRS -10/16 titled Development and PoC validation of a novel approach to treat HIV infection by integrating anti-viral activity with stimulation of host cell innate immunity. The project team has identified and developed a novel drug lead and chemical series possessing novel pharmacology against HIV infection based on medicinal chemistry efforts. The identified lead and chemical series is found to be very potent when screened for anti-viral in vitro screening assays. The lead and few of the congener were also evaluated for other preclinical in vivo pharmacology such as detailed metabolic stability, CYP interaction and dose ranging pharmacokinetic and toxico-kinetic evaluations. The lead molecule and its congener are also found to be safe in animals when evaluated for repeat dose tolerance study in rat and mice. As a last objective of this study and project, project team wants to evaluate the therapeutic efficacy of one of the identified drug lead in animals infected with HIV.

#### **1. TITLE OF THE STUDY:**

Evaluation of small molecule test compound to determine its effect against HIV infection, using a mice model that accurately produces a full human immune system infected by HIV

#### **2. BRIEF SCOPE OF WORK & SPECIFICATIONS**

It is expected that service provider should provide a detailed technical plan with all required details for the expected animal efficacy studies considering scope of work and following bullet points:

1. The scope of work revolves around evaluation of a small molecule drug lead for its efficacy evaluation against HIV infection in Humanized mice experiment infected with HIV.
2. There is a plan to have minimum 7 groups of huMice with minimum 6 mice in each group i.e. Group G1: Vehicle Control; G2: Positive/Standard control (e.g. Elvitegravir); G3: Dose1-1X of test molecule; G4: Dose2-3X of test molecule; G5: Dose3-10X of test molecule; G6: Standard HAART; G7: HAART with Dose 2
3. Each treatment arm shall have Test Compound/Drug lead, vehicle, HAART, Elvitegravir at doses pre-decided before study.
4. The drug lead and all treatment groups shall be dosed single dose per day using oral gavage for 4 weeks using appropriate formulation
5. Body Weight evaluation shall be done weekly; mice will be monitored daily for clinical signs
6. HIV Viral Load determination at W5, W6, W7, W8, W9, W10.
7. Flow Cytometry before HIV infection (W0), before treatment initiation (W5) and at sacrifice (W10)
8. Full human immune system mouse engrafted with fresh human CD34+ stem cell from cord blood
9. There should be a provision for continuous assessment of human immune cells (12 parameters) by flow cytometry (acoustic focalisation for sensitive HIV infected cells in a volume of 20 µl)
10. At least 40% hCD45 over total CD45 for entry in the HIV study as a selection criteria.

11. Mice preferably should be infected with HIV Infection with HIV-1 viruses.
12. HIV viral load determination by quantitative rt-PCR with 1'000 copies lowest sensitivity.
13. The total time to deliver final results should not be more than 120 days after receipt of work order. However, it can be extended based on some valid technical reasons after mutual discussion.

**3. THE APPLICATION SHOULD BE ACCOMPANIED WITH THE FOLLOWING INFORMATION FAILING WITH THE EOI WILL BE SUMMARILY REJECTED:**

- A. A capability statement (Not more than two pages).
- B. A write up on the understanding of the assignment with respect to the aforementioned brief scope of work.
- C. Company/ Organization profile giving details of current activities and management structure.
- D. Evidence of incorporation.
- E. Annual report including balance sheet and profit and loss account statement for the past three years.

**4. EXPECTATIONS FROM THE PROFESSIONAL ORGANIZATION/ AGENCY:**

Apart from the scope of work described in earlier section, the agency is expected to understand the specific needs of THSTI in this endeavor and come up with a complete plan. The representatives from the organization / agency should interact with the concerned officials/Investigators from THSTI to understand the requirement.

**5. PRE-QUALIFICATION OF THE ORGANIZATION :-**

The agency / organization submitting the offer will be shortlisted, who are capable of rendering high degree of professional services in the field. These short listed agencies may be invited later to submit their proposals. Additionally, the agencies/organizations must fulfil the following criteria:-

- A. Should be a reputed and established Pvt or Ltd company having minimum experience of serving at least 2 similar clients. The applicant should have engaged in execution of similar study and completed at least one similar study costing not less than INR 96 Lakh or completed two similar works each costing not less than INR 60 Lakh during the last seven years ending 31.12.18.
- B. Should have solvency of INR 60 Lakhs certified by a nationalized bank or a scheduled Bank or an international bank of repute operating in India with due permission from Reserve Bank of India (RBI) and obtained not earlier than six months before the date of submission of EOI.
- C. The organization should have capacity to deliver within 4 months from the allotment of work order & should be able to support and maintain the study data for 12 months post completion of the study.
- D. Experience in similar type of completed study executed during the last three years and details like monetary value, clients, proof of satisfactory completion.
- E. Documentary evidence of adequate financial standing, Certified by Bankers, Audited Profit & Loss A/c and Balance Sheet, annual turnover in last three (03) years.

- F. Information regarding projects in hand, current work orders, litigation, exclusion/expulsion or black listing, if any.
- G. Service provider should have huMice generation facility with some kind of quality certification in place.
- H. Service provider should have proven and ample historical evidences to support experience in handling, performing and delivering service for HIV hu-mouse model for anti-HIV efficacy studies.
- I. Service provider should be fully authorized to perform the study outline with ethical and national committee approval in a BSL 3 animal and lab facility.
- J. Service provider should be able to boost transiently myeloid lineage differentiation with human GM-CSF, IL3, IL4, IL15 to support HIV antibody based therapies.
- K. Service provider should have a provision for continuous assessment of human immune cells (12 parameters) by flow cytometry.
- L. Service provider should have availability of HARRT and Elvitegravir in sufficient amount for animal dosing as control/comparative arms parallel to study arms.
- M. Undertaking for never been black listed by Centre/State Government/any PSU/private sector. Preference will be given to the agencies/consultants who are currently executing similar type of work

## **6. THE SELECTION PROCESS:**

**The selection process of the applicant for “Evaluation of Small Molecule Test Compound to evaluate its effect against HIV, using a mice model that accurately produces a full human immune system infected by HIV infection” provide the study at THSTI, NCR BIOTECH SCIENCE CLUSTER will comprise of the following steps:**

### **6.1 Invitation for EOI:**

A notice inviting for Expression of Interest has will be published in leading daily newspapers CPP Portal (Govt. of India), shared with prospective embassies and also be uploaded on the THSTI website for wide publicity, as per standard practice of Government of India. This document with key details of the project and response formats is made available to all the potential and interested applicants.

### **6.2 Pre-EOI Meeting:**

A pre-EOI meeting/web based interaction with all the interested applicants is scheduled to be held on 24/07/2019. The venue of the meeting will be THSTI, Faridabad. Interested firms are invited to attend the same with a prior intimation along with a statement of their query.

### **6.3 Notification of amendments:**

If the EOI document requires any modification, suitable amendment to the EOI document will be issued and the same will form part of the EOI document. Corrigendum/amendments etc., if any, will be notified only on the THSTI web site and no separate advertisement will be released for the same. Prospective applicants are therefore advised to regularly visit the THSTI web site for any such updates.

### **6.4 Receipt and Opening of Sealed EOIs:**

The responses from potential applicants who are interested in participating in the selection process will be received in sealed envelopes at the designated place, on a designated date and time as specified in this document. The sealed EOIs will be opened in front of the prospective applicants on a designated date and time by the tender opening committee of THSTI. Late/delayed bids will not be opened and will be returned to the applicants.

## 6.5 Evaluation of EOIs:

A screening process will be adopted for evaluation of the EOI received from the applicants. The bid submitted by the potential applicants as part of the response to this EOI will be evaluated against the minimum eligibility criteria specified in the EOI. Based on this evaluation, the potential applicants who meet the eligibility criteria will be short listed for further consideration by the Committee constituted for the said purpose.

As a result of the above screening process, the name of the applicants who are recommended by the committee will be shortlisted as qualified applicants and only such applicants will become eligible for next step. The list of such qualified applicant will be published on THSTI website. However, committee may ask for more information from shortlisted candidates before making final decision on selection.

## 6.6 Pre-Meeting for Request for Proposal (RFP):

A draft Request for Proposal (RFP) with information on the specific requirements of THSTI will be shared with the applicants who qualify for the screening process and invited for meeting or web based interaction to discuss as well as provide the necessary inputs before finalizing the Request for Proposal (RFP).

## 6.7 Requests for Proposal (RFP):

A detailed Request for Proposal (RFP) with information on the specific requirements of THSTI will be circulated to the qualified applicants. Only the qualified applicants will be invited formally by THSTI to respond to Request for Proposal (RFP) and submit the techno-commercial proposal as per the specifications to be elaborated in the RFP.

## 6.8 Evaluation of the Proposals:

The responses from applicants, who submit their technical and commercial proposals against the requirements of THSTI as specified in the RFP, will be evaluated and the best value bid will be decided based on the criteria which will be elaborated in the RFP documents.

## 7. SUBMISSION OF EOI:

- a. The applicants are advised to study this document carefully before submitting their EOI. It shall be deemed that the EOI has been submitted by the applicant after a careful examination and full understanding of its implications.
- b. The EOI should be submitted in an envelope super-scribed “**EOI for Evaluation of Small Molecule Test Compound to evaluate its effect against HIV, using a mice model that accurately produces a full human immune system infected by HIV infection**” at THSTI, NCR- Biotech Science Cluster, Faridabad”. This envelope should contain all the relevant documents.
- c. The EOI submitted by the agency shall comprise the following;
  - All necessary documents in support of minimum requirements mentioned in section 3.
  - Information in formats as specified in Annexure I.
- d. The submitted EOI should also address the following points:
  - Complete overview of the project Plan, structure and team – with project timelines and expertise to be deployed for the project.
- e. The envelope shall indicate the name and address of the applicants to identify the EOI and to enable the EOI to be returned unopened in case it is declared ‘late’ or ‘rejected’.

- f. The EOI may be sent by the applicants by Courier/Speed-post, with the envelope marked as above to the following address:

**The Executive Director,  
(Purchase Section)**

Translational Health Science and Technology Institute,  
NCR BIOTECH SCIENCE CLUSTER,  
3rd Milestone, Faridabad-Gurgaon Expressway,  
PO Box No. 04,  
Faridabad - 121 001  
Haryana (NCR Delhi), India

- g. Alternatively, EOI may also be deposited by the applicants in the tender box kept in THSTI, Purchase Section, NCR BIOTECH SCIENCE CLUSTER, 3rd Milestone, Faridabad-Gurgaon Expressway, Faridabad - 121 001, Haryana (NCR Delhi).
- h. The EOI submitted shall remain valid for acceptance for a period of 90 days from the date of opening of EOI document.
- i. EOIs received through Fax/E-mail or through open letter shall be rejected.
- j. Any EOI received late/after the deadline for submission of the bids shall be rejected and returned unopened to the applicant.

**7.1 CLARIFICATIONS ON EOIs:**

To assist evaluation and comparison of the EOIs, the THSTI, NCR BIOTECH SCIENCE CLUSTER may at its discretion ask the applicant for clarification on the EOI. The clarification and response from applicant shall be in writing.

**7.2 CANCELLING THE EOI:**

The Executive Director, THSTI reserves the right to cancel/reject the EOI and any or all the bids without assigning any reason whatsoever at any time/stage.

**8. DISCLOSURES:**

Any change in the constitution of the agency's firm, where it is a partnership firm, as declared in the prequalification documents submitted by the applicant at the time of submission of pre-qualification documents, should be disclosed to the THSTI, at any time between the submission of bids and the signing of the contract.



**Annexure I**

Using the relevant Forms given in this Annexure I, Applicants are required to submit the all relevant details along with documentary proofs in claim of their eligibility:

**Bid Formats / Forms**

**Form-1: Letter of Transmittal**

*(to be submitted on the letter head of the applicant)*

To  
The Executive Director,  
Translational Health Science and Technology Institute,  
NCR BIOTECH SCIENCE CLUSTER,  
3rd Milestone, Faridabad-Gurgaon Expressway,  
PO Box No. 04,  
Faridabad - 121 001, Haryana (NCR Delhi), India  
Phone: 91 129 2876437

Subject: Submission of EOI for **“Evaluation of Small Molecule Test Compound to evaluate its effect against HIV, using a mice model that accurately produces a full human immune system infected by HIV infection”**”.

Dear Sir/Madam,

Having examined the details given in press notification and the EOI document, I/We, the undersigned, offer to provide services to THSTI, NCR BIOTECH SCIENCE CLUSTER activities for Evaluation of Small Molecule Test Compound to evaluate its effect against HIV, using a mice model that accurately produces a full human immune system infected by HIV infection” in response to your notice inviting EOI dated..... I/We are hereby submit the EOI documents and all other relevant information.

I/We hereby certify that all the statements made and information supplied in the enclosed forms and accompanying statements are true and correct.

I/We have furnished all information and details necessary for eligibility criteria and have no further pertinent information to supply.

I/We submit the requisite certified solvency certificate and authorize the Executive Director, THSTI to approach the Bank issuing the solvency certificate to confirm the correctness thereof and also to approach individuals, employers and firms to verify our competence and general reputation.

I/We accept that any misinterpretation contained in it may lead to our disqualification and rejection of the EOI.

I/We submit the following certificates in support of our suitability, technical knowhow & capability for having successfully completed the following similar works.

Nature of Work	Year of Completion	Certificate From
1.		
2.		
3.		

I/We also understand that you are not bound to accept any proposal you receive.

Yours faithfully,

Authorised signature *(in full and initials)* .....

Name and designation of the signatory .....

Name of the Firm .....

Business address .....

Office seal.....

Place.....

Date .....

**Form-2: Applicant's Authorization Certificate**

*(to be submitted on the letter head of applicant)*

To  
The Executive Director,  
Translational Health Science and Technology Institute,  
NCR BIOTECH SCIENCE CLUSTER,  
3rd Milestone, Faridabad-Gurgaon Expressway,  
PO Box No. 04,  
Faridabad - 121 001  
Haryana (NCR Delhi), India  
Phone: 91 129 2876437

Dear Sir/Madam,

**<Applicant's Name>**, **<Designation>** is hereby authorized to sign relevant documents on behalf of the company in dealing with Tender of reference (Tender No. & Date)

\_\_\_\_\_ He is also authorized to attend meetings and submit technical and commercial information as may be required by you in the course of processing above said tender.

Yours faithfully,

Authorized signature *(in full and initials)* .....

Name and designation of the signatory .....

.....

Name of the Firm .....

Business address .....

Office seal.....

Place.....

Date .....

**Form-3: Self Declaration**

*(to be submitted on the letter head of the applicant)*

Ref: .....

Date .....

To  
The Executive Director,  
Translational Health Science and Technology Institute,  
NCR BIOTECH SCIENCE CLUSTER,  
3rd Milestone, Faridabad-Gurgaon Expressway,  
PO Box No. 04,  
Faridabad - 121 001 Haryana (NCR Delhi), India  
Phone: 91 129 2876437

Dear Sir/Madam,

In response to the EOI No. \_\_\_\_\_ dated \_\_\_\_\_, as  
Owner/Partner/Director \_\_\_\_\_ I/We hereby declare that our  
Agency \_\_\_\_\_ is having unblemished past record and was not declared  
ineligible for corrupt and fraudulent practices either indefinitely or for a particular period of time.

We understand that in case the above information is found incorrect, our EOI will be rejected.

Yours faithfully,

Authorised signature *(in full and initials)* .....

Name and designation of the signatory .....  
.....

Name of the Firm .....

Business address .....

Office seal.....

Place.....

Date .....

**Form-4: Certificate of Conformity**

*(to be submitted on the letter head of the applicant)*

To

The Executive Director,  
Translational Health Science and Technology Institute,  
NCR BIOTECH SCIENCE CLUSTER,  
3rd Milestone, Faridabad-Gurgaon Expressway,  
PO Box No. 04,  
Faridabad - 121 001  
Haryana (NCR Delhi), India  
Phone: 91 129 2876437

**CERTIFICATE**

This is to certify that, the services for Evaluation of Small Molecule Test Compound to evaluate its effect against HIV, using a mice model that accurately produces a full human immune system infected by HIV infection” which I shall provide, if I am awarded with the work, are in conformity with the Scope of Work in the EOI document.

Yours faithfully,

Authorised signature *(in full and initials)* .....

Name and designation of the signatory .....

.....

Name of the Firm .....

Business address .....

Office seal.....

Place.....

Date .....

**Form-6: Financial Information**

- I. Financial Analysis- Details to be furnished duly supported by figures in balance sheet/profit & loss account for last three years duly certified by the Chartered Accountant or Competent authority, as submitted by the applicant to the Income Tax Department (Copies to be attached)

Particulars/Year	2015-16	2016-17	2017-18
Annual Turnover			
Net Profit/Loss			

- II. Financial arrangements for undertaking the proposed Study.  
III. Solvency certificate from Bankers of the applicant in the prescribed form "7"

*Note :- Please attach copies of relevant financial statements and audited accounts for the last three declared financial year*

**Form-7: Form of Bankers' Certificate from a Bank**

This is to certify that to the best of our knowledge and information that;

\_\_\_\_\_

(Name of the individual or the firm)

\_\_\_\_\_

(Name of the proprietor in case of a sole proprietorship concern or names of partners in case of partnership concern as per bank's record, be indicated)

\_\_\_\_\_

(Address of the customer as per bank record)

is a / are customer(s) of our bank, is/are respectable and can be treated as good for any engagement up to a limit of INR. \_\_\_\_\_

[INR (In words) \_\_\_\_\_ only]

This certificate is issued without any guarantee or responsibility on the bank or any of the officers.

Signature of the Manager

Seal of Bank

Note: This certificate should be issued on the letter head and addressed to the EXECUTIVE DIRECTOR, TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE, NCR BIOTECH SCIENCE CLUSTER, 3<sup>RD</sup> MILESTONE, FARIDABAD-GURGAON EXPRESSWAY, PO BOX NO. 04, FARIDABAD - 121 001, HARYANA (NCR DELHI), INDIA in a Sealed Cover

**Form-8: Details of all similar works completed during the last 3 (three) Years ending last day of the month**

S. No.	Name of work/ project and location	Owner or Sponsoring organization	Cost of work in crores of INR	Date of commencement As per contract	Stipulated date of completion	Actual date of completion	Number of staff deployed in the assignment	*Benchmarked Accreditations Achieved (if any)	Litigation / arbitration cases pending/in progress with details	Name and Address / Contact details of officer to whom reference may be made	Remarks
1	2	3	4	5	6	7	8		9	10	11

- Indicate gross amount claimed and amount awarded by the Arbitrator.

Authorized signature *(in full and initials)* .....

Name and designation of the signatory .....

.....

Name of the Firm .....

Business address .....

Office seal.....

Place.....

Date .....

Note: Please attach the proofs-work orders, relevant certificates or letter of appointments etc. with the credential.

**Form-9: Details of similar projects under execution or awarded**

S. No.	Name of work/ project and location	Owner or Sponsoring organization	Cost of work in crores of INR	Date of commencement As per contract	Stipulated date of completion	Actual date of completion	Number of staff deployed in the assignment	*Benchmarked Accreditations Planned (if any)	Present Status	Litigation / arbitration cases pending/in progress with details	Name and Address / Contact details of officer to whom reference may be made	Remarks
1	2	3	4	5	6	7	8			9	10	11

Certified that the above list of works is completed and no work has been left out that the information given is corrected to our/my knowledge and belief.

Authorized signature (*in full and initials*) .....

Name and designation of the signatory .....

.....

Name of the Firm .....

Business address .....

Office seal.....

Place.....

Date .....

Note: Please attach the proofs-work orders, relevant certificates or letter of appointments etc. with the credential.



**Form-10: Performance report of works referred in form 8 & 9**

1. Name of the work:
2. Project & Location:
3. Agreement No.:
4. Estimated Cost:
5. Project Cost:
6. Date of Start:
7. Date of completion
  - (a) Stipulated date of completion:
  - (b) Actual date of completion:
8. Amount of compensation levied for delayed Completion if any:
9. Present Status:
10. Performance report:
  - i) Quality of Work : Excellent / Good / Fair / Poor
  - ii) Financial Soundness : Excellent / Good / Fair / Poor
  - iii) Technical Proficiency : Excellent / Good / Fair / Poor
  - iv) Resourcefulness : Excellent / Good / Fair / Poor
  - v) General Behaviour / Conduct : Excellent / Good / Fair / Poor

Dated:

Authorized Signatory

### **Form-11: Structure and Organization**

1. Name and address of the applicant.
2. Telephone No./Telex No./Fax No./E-mail.
3. Incorporation Year.
4. Legal Status (attach copies of original Document defining the legal status).
  - (a) An Individual.
  - (b) A proprietary Firm.
  - (c) A Firm in partnership.
  - (d) A private limited or limited Company or Corporation.
5. Particulars of registration with various Government bodies (Attach attested photo-copy).
  - a) Registration Number.
  - b) Organization / Place of registration.
6. Names and Titles of Directors and officers with designation to be concerned with this work.
7. Designation of individuals authorized to act for the organization.
8. Was the applicant ever required to suspend consultation services for a period of more than six months continuously after you commenced the contract? If so, give the name of the project and reasons of suspension of that.
9. Has the applicant, or any constituent partner in case of partnership firm, ever abandoned the awarded work before its completion? If so, give the name of the project and give reasons for abandonment.
10. Has the applicant or any constituent partner in case of partnership firm, ever been debarred / black listed for tendering in any organization at any time? If so, give details.
11. Has the applicant or any constituent partner in case of partnership firm, ever been convicted by a court of law? If so, give detail.
12. In which field of animal facility development and management, the applicant has specialization and interest?
13. Any other information considered necessary but not included above.

SIGNATURE OF THE APPLICANT(S)

**Form-12: Manpower Details (to be deployed for study)**

*(On Applicant's letter head)*

S.No.	Designation	Strength / Expertise	Time period of engagement for this project	Name	Qualification	Professional Experience and details of work executed	Purpose of involvement in this Project	Remarks
1	2	3	4	5	6	7	8	9

Authorized signature *(in full and initials)* .....

Name and designation of the signatory .....

.....

Name of the Firm .....

Business address .....

Office seal.....

Place.....

Date .....

Note: Please enclose the brief profile or resume of these proposed manpower.